Metformin and cancer mortality | Zendy

Lev Bershteyn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metformin and cancer mortality

Author(s) -

Lev Bershteyn

Publication year - 2010

Publication title -

diabetes mellitus

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.155

H-Index - 12

eISSN - 2072-0378

pISSN - 2072-0351

DOI - 10.14341/2072-0351-5491

Subject(s) - metformin , medicine , cancer , type 2 diabetes mellitus , diabetes mellitus , insulin resistance , oncology , intensive care medicine , bioinformatics , endocrinology , biology

The author analyses recent publications supporting the ability of metformin to decrease the risk of cancer morbidity and mortality in patients with type 2diabetes mellitus. Pre-history of the problem (including the use of biguanides for metabolic rehabilitation of oncological patients), the role of DM as a riskfactor of cancer morbidity and mortality, mechanisms and targets of metformin anticancer effects, and potential use of this agent in non-diabetic patientsare discussed. The need for the search of the markers of sensitivity and resistance to metformin to be used in oncological practice is emphasized.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research